BR112013013548B8 - Proteína de fusão anticancerígena - Google Patents

Proteína de fusão anticancerígena

Info

Publication number
BR112013013548B8
BR112013013548B8 BR112013013548A BR112013013548A BR112013013548B8 BR 112013013548 B8 BR112013013548 B8 BR 112013013548B8 BR 112013013548 A BR112013013548 A BR 112013013548A BR 112013013548 A BR112013013548 A BR 112013013548A BR 112013013548 B8 BR112013013548 B8 BR 112013013548B8
Authority
BR
Brazil
Prior art keywords
fusion protein
domain
sequence
cancer fusion
terminus
Prior art date
Application number
BR112013013548A
Other languages
English (en)
Other versions
BR112013013548B1 (pt
BR112013013548A2 (pt
Inventor
Szczepan Pieczykolan Jerzy
Kazimierz Lemke Krzysztof
Pawlak Sebastian
Zerek Bartlomiej
Original Assignee
Adamed Sp Zoo
Adamed Pharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PL393146A external-priority patent/PL393146A1/pl
Application filed by Adamed Sp Zoo, Adamed Pharma S A filed Critical Adamed Sp Zoo
Publication of BR112013013548A2 publication Critical patent/BR112013013548A2/pt
Publication of BR112013013548B1 publication Critical patent/BR112013013548B1/pt
Publication of BR112013013548B8 publication Critical patent/BR112013013548B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROTEÍNA DE FUSÃO ANTICANCERÍGENA Uma proteína de fusão compreendendo o domínio (a) que é um fragmento funcional da sequência da proteína hTRAIL, tal fragmento começa com um aminoácido em uma posição não inferior a hTRAIL95, ou um homólogo do referido fragmento funcional tendo pelo menos 70% de identidade de sequência, e domínio (b) que é uma sequência de um peptídeo efetor imunoestimulante, em que a sequência do domínio (b) 10 está ligada ao C-terminal ou N-terminal do domínio (a). A proteína de fusão pode ser usada para o tratamento de doenças cancerosas.
BR112013013548A 2010-12-03 2011-12-05 Proteína de fusão anticancerígena BR112013013548B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PL393146A PL393146A1 (pl) 2010-12-03 2010-12-03 Przeciwnowotworowe białko fuzyjne
PLP.393146 2010-12-03
PL39459711 2011-04-18
PLP.394597 2011-04-18
PCT/EP2011/071719 WO2012072815A1 (en) 2010-12-03 2011-12-05 Anticancer fusion protein

Publications (3)

Publication Number Publication Date
BR112013013548A2 BR112013013548A2 (pt) 2016-10-11
BR112013013548B1 BR112013013548B1 (pt) 2022-03-29
BR112013013548B8 true BR112013013548B8 (pt) 2022-11-08

Family

ID=45065918

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013013548A BR112013013548B8 (pt) 2010-12-03 2011-12-05 Proteína de fusão anticancerígena

Country Status (27)

Country Link
US (1) US9161991B2 (pt)
EP (1) EP2646464B1 (pt)
JP (1) JP5759557B2 (pt)
KR (1) KR101952460B1 (pt)
CN (1) CN103237808B (pt)
AU (1) AU2011334868B2 (pt)
BR (1) BR112013013548B8 (pt)
CA (1) CA2814595C (pt)
CY (1) CY1116646T1 (pt)
DK (1) DK2646464T3 (pt)
EA (1) EA024452B1 (pt)
ES (1) ES2545895T3 (pt)
HK (1) HK1186192A1 (pt)
HR (1) HRP20150664T1 (pt)
HU (1) HUE027068T2 (pt)
IL (1) IL226207A (pt)
ME (1) ME02224B (pt)
MX (1) MX337436B (pt)
NZ (1) NZ609216A (pt)
PL (1) PL2646464T3 (pt)
PT (1) PT2646464E (pt)
RS (1) RS54057B1 (pt)
SG (2) SG10201509676UA (pt)
SI (1) SI2646464T1 (pt)
SM (1) SMT201500203B (pt)
WO (1) WO2012072815A1 (pt)
ZA (1) ZA201303449B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL219845B1 (pl) * 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
WO2012106281A2 (en) 2011-01-31 2012-08-09 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
EP2877572B1 (en) 2012-07-24 2018-11-28 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
WO2014057436A2 (en) 2012-10-10 2014-04-17 Adamed Sp. Z O.O. Anticancer conjugate
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
US10428132B2 (en) 2015-02-11 2019-10-01 West China Hospital, Sichuan University Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
CN106632682A (zh) * 2015-08-04 2017-05-10 清华大学 融合蛋白ifn-elp及其应用
JP2022529943A (ja) 2019-04-15 2022-06-27 クウィクセル セラピューティクス リミテッド ライアビリティ カンパニー がんの処置における使用のための、標的指向性のマスクされたｉ型インターフェロン（ｉｆｎａおよびｉｆｎｂ）と腫瘍抗原に対する抗体とを含む融合タンパク質組成物
BR112022020440A2 (pt) 2020-04-10 2022-12-27 Cytomx Therapeutics Inc Construtos de citocinas ativáveis e composições e métodos relacionados
BR112023018735A2 (pt) 2021-03-16 2023-11-28 Cytomx Therapeutics Inc Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
KR20230169700A (ko) 2022-06-09 2023-12-18 제주대학교 산학협력단 Trail을 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JP4435304B2 (ja) 1995-06-29 2010-03-17 イミュネックス・コーポレーション アポトーシスを誘導するサイトカイン
DK1351709T3 (da) * 2000-06-09 2005-01-31 Us Gov Health & Human Serv Pegylering af linkere forbedrer antitumorvirkning og reducerer immunkonjugaters tokcitet
DE60141992D1 (pt) * 2000-09-05 2010-06-10 Biosight Ltd
DE10247755B4 (de) 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
CN100549175C (zh) 2003-11-03 2009-10-14 沙东生物药业（天津）有限公司 一种具有抑癌作用的重组蛋白及其编码基因与应用
ZA200800969B (en) 2005-08-16 2009-08-26 Genentech Inc Apoptosis sensitivity to APO2L/TRAIL by testing for GalNac-T14 expression in cells/tissues
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
CA2860950C (en) * 2007-07-10 2017-08-01 Apogenix Gmbh Tnf superfamily collectin fusion proteins
EP3492488A1 (en) * 2007-08-22 2019-06-05 The Regents of The University of California Activatable binding polypeptides and methods of identification and use thereof
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
US7943733B2 (en) 2007-12-20 2011-05-17 University Of Southern California Spacers to increase the expression of recombinant fusion proteins
TW200950778A (en) 2008-05-14 2009-12-16 Genentech Inc Methods of using Apo2L/TRAIL to treat cancer
LT2010012A (lt) 2010-02-10 2011-08-25 Uab Profarma, , Granulocitus stimuliuojančio baltymo linijiniai oligomerai su prailginta in vivo gyvavimo trukme

Also Published As

Publication number Publication date
WO2012072815A1 (en) 2012-06-07
EA024452B1 (ru) 2016-09-30
CA2814595A1 (en) 2012-06-07
NZ609216A (en) 2014-05-30
EP2646464B1 (en) 2015-06-03
BR112013013548B1 (pt) 2022-03-29
IL226207A0 (en) 2013-07-31
ZA201303449B (en) 2014-01-29
BR112013013548A2 (pt) 2016-10-11
ME02224B (me) 2016-02-20
EP2646464A1 (en) 2013-10-09
CN103237808B (zh) 2016-02-24
CA2814595C (en) 2020-06-16
KR101952460B1 (ko) 2019-02-27
CN103237808A (zh) 2013-08-07
MX337436B (es) 2016-03-03
KR20130122764A (ko) 2013-11-08
IL226207A (en) 2016-07-31
SI2646464T1 (sl) 2015-07-31
RS54057B1 (en) 2015-10-30
SG189370A1 (en) 2013-05-31
HUE027068T2 (en) 2016-08-29
DK2646464T3 (en) 2015-08-24
EA201390820A1 (ru) 2013-12-30
SMT201500203B (it) 2015-10-30
PL2646464T3 (pl) 2015-10-30
SG10201509676UA (en) 2015-12-30
JP2014502158A (ja) 2014-01-30
MX2013006213A (es) 2013-07-29
CY1116646T1 (el) 2017-03-15
AU2011334868A1 (en) 2013-05-02
PT2646464E (pt) 2015-10-05
HRP20150664T1 (hr) 2015-07-31
ES2545895T3 (es) 2015-09-16
AU2011334868B2 (en) 2015-01-22
HK1186192A1 (en) 2014-03-07
US20130251676A1 (en) 2013-09-26
JP5759557B2 (ja) 2015-08-05
US9161991B2 (en) 2015-10-20

Similar Documents

Publication Publication Date Title
BR112013013548B8 (pt) Proteína de fusão anticancerígena
BR112012032708A2 (pt) proteína de fusão anticâncer.
PH12014501083A1 (en) Anticancer fusion protein
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
MX2013007872A (es) Proteina de fusion anticancer.
BR112013029525A2 (pt) proteínas de fusão terapêuticas
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
NZ627111A (en) Variants of activin iib receptor polypeptides and uses thereof
EA201491277A1 (ru) Противораковый слитый белок
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BR112013025975A2 (pt) proteína de fusão anticancerígena
BR112017019625A2 (pt) udp-glicosiltransferases
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
BR112016010643A2 (pt) peptídeo
BR112021023957A2 (pt) Peptídeos
BR112013032088A2 (pt) "polipeptídeo, composição farmacêutica e seu uso"
BR112018012055A2 (pt) substrato de transglutaminase (tg) recombinante, método in vitro para marcar uma proteína de interesse, composição farmacêutica ou de diagnóstico e kit de diagnóstico
BR112017010775A2 (pt) ?método para produzir um produto de conjugação enzimática?
BR112015017909A2 (pt) redução do risco de doença autoimune
BR112015023651A2 (pt) expressão aumentada de proteínas de picornavírus
BR112018001207A2 (pt) novo peptídeo e uso do mesmo
BRPI0715331B8 (pt) polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo
BR112013011285A2 (pt) vacina
BR112013002702A2 (pt) vacina
ES2421885T3 (es) Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.2 NA RPI NO 2651 DE 26/10/2021 POR TER SIDO INDEVIDA.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25A Requested transfer of rights approved

Owner name: ADAMED PHARMA S.A. (PL)